Oncogenes that occur in≤ 5% of non-small-cell lung cancers have been defined as 'rare';
nonetheless, this frequency can correspond to a substantial number of patients diagnosed …

Metastasis remains a pivotal characteristic of cancer and is the primary contributor to cancer-
associated mortality. Despite its significance, the mechanisms governing metastasis are not …

Trastuzumab deruxtecan (T-DXd) intracranial activity has been observed in small or
retrospective patient cohorts with human epidermal growth factor receptor 2–positive …

Abstract Antibody–drug conjugates (ADCs), a class of targeted cancer therapeutics
combining monoclonal antibodies with a cytotoxic payload via a chemical linker, have …

Abstract DESTINY-Breast01 (NCT03248492) evaluated trastuzumab deruxtecan (T-DXd; DS-
8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC). We …

Purpose: Brain metastases can occur in up to 50% of patients with metastatic HER2-positive
breast cancer. Because patients with active brain metastases were excluded from previous …

Amplification and/or overexpression of ERBB2, the gene encoding HER2, can be found in
15–20% of invasive breast cancers and is associated with an aggressive phenotype and …

The identification of the HER2 alteration as an actionable oncogenic driver in breast cancer
has propelled the development of HER-targeting monoclonal antibodies (mAb) such as …

Breast cancer (BC) is one of the most widely diagnosed cancers and a leading cause of
cancer death among women worldwide. Globally, BC is the second most frequent cancer …

Breast cancer is one of the main cause of cerebral and leptomeningeal metastases, the
prognosis of which remains poor to this day. Most studies excluded patients with active brain …